Daphne Koller

Share SOUTH SAN FRANCISCO, Calif. – October 6, 2026 – insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitro and, critically, in vivo properties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained

View original ↗

Artificial intelligence (AI) is changing the way biomedical research is conducted by making it possible to integrate diverse types of biological data and tackle questions that were previously difficult to address. At the same time, its growing use also raises important questions about data quality, reliability, interpretability, and how computational predictions should be combined with biological knowledge and experi

View original ↗

Collaboration expands to include two additional therapeutic targets for the treatment of ALS discovered via insitro’s AI-driven Virtual Human™ platform Joint effort focuses on identifying key biological drivers to deliver disease-modifying interventions for ALS patients SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the expansion of its stra

View original ↗

Share How insitro unlocked population-scale human genetics in a tissue that has resisted measurement for decades – and what it reveals about peripheral approaches to metabolic disease The Furnace We Couldn’t See The human body contains a type of fat tissue engineered to burn energy rather than store it. Brown adipose tissue – dense with mitochondria, rich in uncoupling proteins – converts glucose and lipids into heat

View original ↗

Share AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in preclinical models through peripheral adipose beiging, preserving lean mass Key findings presented at the Keystone Symposia on Obesity Therapeutics SOUTH SAN FRANCISCO, Calif. – Feb 2, 2026 – insitro, the AI therapeutics company built on causal biology, today repo

View original ↗

Share TherML™ integrates CombinAbleAI’s advanced, next generation biologics expertise with insitro’s existing small molecule and oligonucleotide capabilities, unifying therapeutic design across all major drug modalities in a single AI engine SOUTH SAN FRANCISCO, Calif. – Jan. 12, 2026 – insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insi

View original ↗

Share New publication demonstrates that insitro’s POSH platform — integrating pooled CRISPR screening and self-supervised deep learning — successfully breaks the historic compromise between scale and depth to more rapidly identify novel therapeutic targets. SOUTH SAN FRANCISCO, Calif. — Dec. 16, 2025 — insitro, the AI therapeutics company built on causal biology, today announced the publication of research in Nature

View original ↗